IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient
News
The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, the ... Read more